| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Merve Atli, James C Bennett, Megan Croal, Charles DeBattista, Boadie W Dunlop, David Feifel, David J Hellerstein, Muhammad Ishrat Husain, John R Kelly, Molly R Lennard-Jones, Rasmus W Licht, Lindsey Marwood, Sunil Mistry, Tomáš Páleníček, Ozlem Redjep, Dimitris Repantis, Robert A Schoevers, Batya Septimus, Hollie J Simmons, Jair C Soares, Metten Somers, Susan C Stansfield, Jessica Rose Stuart, Hannah H Tadley, Nisha K Thiara, Joyce Tsai, Mourad Wahba, Sam Williams, Rachel I Winzer, Allan H Young, Matthew B Young, Sid Zisook, Ekaterina Malievskai. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of affective disorders. 2023-02-05. PMID:36740140. |
comp360 is a proprietary, synthetic formulation of psilocybin being developed for treatment-resistant depression (trd), a burdensome, life-threatening illness with high global impact. |
2023-02-05 |
2023-08-14 |
Not clear |
| Alejandro Torrado Pacheco, Randall J Olson, Gabriela Garza, Bita Moghadda. Acute psilocybin enhances cognitive flexibility in rats. bioRxiv : the preprint server for biology. 2023-01-30. PMID:36712091. |
psilocybin has been shown to improve symptoms of depression and anxiety when combined with psychotherapy or other clinician-guided interventions. |
2023-01-30 |
2023-08-14 |
rat |
| Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini, Giuseppina Cantarell. Psilocybin for Depression: From Credibility to Feasibility, What's Missing? Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678564. |
psilocybin for depression: from credibility to feasibility, what's missing? |
2023-01-21 |
2023-08-14 |
Not clear |
| Robin von Rotz, Eva M Schindowski, Johannes Jungwirth, Anna Schuldt, Nathalie M Rieser, Katharina Zahoranszky, Erich Seifritz, Albina Nowak, Peter Nowak, Lutz Jäncke, Katrin H Preller, Franz X Vollenweide. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. vol 56. 2023-01-13. PMID:36636296. |
psilocybin has been suggested as a novel, rapid-acting treatment for depression. |
2023-01-13 |
2023-08-14 |
Not clear |
| Ricardo Irizarry, Amelia Winczura, Omar Dimassi, Navpreet Dhillon, Annu Minhas, Jeanpaul Laric. Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. Cureus. vol 14. issue 11. 2022-12-26. PMID:36569662. |
another analysis was done using depression severity (quick inventory of depressive symptomatology 16-item self report, qids-sr16) at baseline and after the use of psilocybin. |
2022-12-26 |
2023-08-14 |
human |
| Juliet Meccia, Joëlle Lopez, Rosemary C Bago. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. Psychopharmacology. 2022-12-23. PMID:36564671. |
we highlight the potential for preclinical circuit and behavioral neuroscience approaches to provide basic mechanistic insight into how psilocybin modulates cognitive and affective neural circuits to support further development of psilocybin as a promising new treatment for depression. |
2022-12-23 |
2023-08-14 |
human |
| Meghan DellaCrosse, Mollie Pleet, Emma Morton, Amir Ashtari, Kimberly Sakai, Josh Woolley, Erin Michala. "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PloS one. vol 17. issue 12. 2022-12-14. PMID:36516137. |
emerging evidence suggests psilocybin, the psychoactive compound in "magic mushrooms," is a promising treatment for unipolar depression. |
2022-12-14 |
2023-08-14 |
Not clear |
| Gregory Barber, Charles B Nemeroff, Steven Siege. A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. The American journal of psychiatry. vol 179. issue 12. 2022-12-01. PMID:36453037. |
a case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability. |
2022-12-01 |
2023-08-14 |
Not clear |
| Melissa Shukuroglou, Leor Roseman, Matt Wall, David Nutt, Mendel Kaelen, Robin Carhart-Harri. Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. Journal of psychopharmacology (Oxford, England). 2022-11-26. PMID:36433778. |
changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. |
2022-11-26 |
2023-08-14 |
Not clear |
| Dev B Goel, Sarju Zilat. Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus. vol 14. issue 10. 2022-11-16. PMID:36381758. |
according to three controlled studies, psilocybin may reduce symptoms of depression and anxiety in the context of cancer-related psychological discomfort for at least six months after a single acute treatment for mood and anxiety disorders. |
2022-11-16 |
2023-08-14 |
Not clear |
| Bertha K Madra. Psilocybin in Treatment-Resistant Depression. The New England journal of medicine. vol 387. issue 18. 2022-11-02. PMID:36322849. |
psilocybin in treatment-resistant depression. |
2022-11-02 |
2023-08-14 |
Not clear |
| Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Peter C Arden, Annie Baker, James C Bennett, Catherine Bird, Renske E Blom, Christine Brennan, Donna Brusch, Lisa Burke, Kete Campbell-Coker, Robin Carhart-Harris, Joseph Cattell, Aster Daniel, Charles DeBattista, Boadie W Dunlop, Katherine Eisen, David Feifel, MacKenzie Forbes, Hannah M Haumann, David J Hellerstein, Astrid I Hoppe, Muhammad I Husain, Luke A Jelen, Jeanine Kamphuis, Julie Kawasaki, John R Kelly, Richard E Key, Ronit Kishon, Stephanie Knatz Peck, Gemma Knight, Martijn H B Koolen, Melanie Lean, Rasmus W Licht, Jessica L Maples-Keller, Jan Mars, Lindsey Marwood, Martin C McElhiney, Tammy L Miller, Arvin Mirow, Sunil Mistry, Tanja Mletzko-Crowe, Liam N Modlin, René E Nielsen, Elizabeth M Nielson, Sjoerd R Offerhaus, Veronica O'Keane, Tomáš Páleníček, David Printz, Marleen C Rademaker, Aumer van Reemst, Frederick Reinholdt, Dimitris Repantis, James Rucker, Samuel Rudow, Simon Ruffell, A John Rush, Robert A Schoevers, Mathieu Seynaeve, Samantha Shao, Jair C Soares, Metten Somers, Susan C Stansfield, Diane Sterling, Aaron Strockis, Joyce Tsai, Lucy Visser, Mourad Wahba, Samuel Williams, Allan H Young, Paula Ywema, Sidney Zisook, Ekaterina Malievskai. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine. vol 387. issue 18. 2022-11-02. PMID:36322843. |
single-dose psilocybin for a treatment-resistant episode of major depression. |
2022-11-02 |
2023-08-14 |
Not clear |
| Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Peter C Arden, Annie Baker, James C Bennett, Catherine Bird, Renske E Blom, Christine Brennan, Donna Brusch, Lisa Burke, Kete Campbell-Coker, Robin Carhart-Harris, Joseph Cattell, Aster Daniel, Charles DeBattista, Boadie W Dunlop, Katherine Eisen, David Feifel, MacKenzie Forbes, Hannah M Haumann, David J Hellerstein, Astrid I Hoppe, Muhammad I Husain, Luke A Jelen, Jeanine Kamphuis, Julie Kawasaki, John R Kelly, Richard E Key, Ronit Kishon, Stephanie Knatz Peck, Gemma Knight, Martijn H B Koolen, Melanie Lean, Rasmus W Licht, Jessica L Maples-Keller, Jan Mars, Lindsey Marwood, Martin C McElhiney, Tammy L Miller, Arvin Mirow, Sunil Mistry, Tanja Mletzko-Crowe, Liam N Modlin, René E Nielsen, Elizabeth M Nielson, Sjoerd R Offerhaus, Veronica O'Keane, Tomáš Páleníček, David Printz, Marleen C Rademaker, Aumer van Reemst, Frederick Reinholdt, Dimitris Repantis, James Rucker, Samuel Rudow, Simon Ruffell, A John Rush, Robert A Schoevers, Mathieu Seynaeve, Samantha Shao, Jair C Soares, Metten Somers, Susan C Stansfield, Diane Sterling, Aaron Strockis, Joyce Tsai, Lucy Visser, Mourad Wahba, Samuel Williams, Allan H Young, Paula Ywema, Sidney Zisook, Ekaterina Malievskai. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine. vol 387. issue 18. 2022-11-02. PMID:36322843. |
psilocybin is being studied for use in treatment-resistant depression. |
2022-11-02 |
2023-08-14 |
Not clear |
| Richard Balo. Are Magic Mushrooms Really Magic?: Psilocybin in the Treatment of Depression. Journal of clinical psychopharmacology. 2022-10-17. PMID:36251379. |
: psilocybin in the treatment of depression. |
2022-10-17 |
2023-08-14 |
Not clear |
| Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha, Urszula Łopuszańska, Jacek Kurzepa, Marzena Samardakiewic. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International journal of molecular sciences. vol 23. issue 19. 2022-10-14. PMID:36232748. |
the pubmed/medline database was used to identify articles for systematic review, using the following search terms: (depression) and (psilocybin) or (ketamine). |
2022-10-14 |
2023-08-14 |
Not clear |
| Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha, Urszula Łopuszańska, Jacek Kurzepa, Marzena Samardakiewic. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International journal of molecular sciences. vol 23. issue 19. 2022-10-14. PMID:36232748. |
three articles were devoted to psilocybin in depression treatment and nine to esketamine. |
2022-10-14 |
2023-08-14 |
Not clear |
| Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha, Urszula Łopuszańska, Jacek Kurzepa, Marzena Samardakiewic. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International journal of molecular sciences. vol 23. issue 19. 2022-10-14. PMID:36232748. |
both esketamine and psilocybin demonstrated rapid and long-term effects in reducing depression symptoms and, after overcoming some limitations, may be considered as novel antidepressant agents in future. |
2022-10-14 |
2023-08-14 |
Not clear |
| Ashley Lyon. Self-administration of Psilocybin in the Setting of Treatment-resistant Depression. Innovations in clinical neuroscience. vol 19. issue 7-9. 2022-10-07. PMID:36204170. |
self-administration of psilocybin in the setting of treatment-resistant depression. |
2022-10-07 |
2023-08-14 |
Not clear |
| Tommaso Barba, Sarah Buehler, Hannes Kettner, Caterina Radu, Bruna Giribaldi Cunha, David J Nutt, David Erritzoe, Leor Roseman, Robin Carhart-Harri. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych open. vol 8. issue 5. 2022-09-06. PMID:36065128. |
effects of psilocybin versus escitalopram on rumination and thought suppression in depression. |
2022-09-06 |
2023-08-14 |
Not clear |
| Arny Johannesdottir, Engilbert Sigurdsso. [The use of psilocybin for treatment-resistant depression]. Laeknabladid. vol 108. issue 9. 2022-08-30. PMID:36040772. |
[the use of psilocybin for treatment-resistant depression]. |
2022-08-30 |
2023-08-14 |
human |